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ing doesn’t tell us why some country like UK perform well while others like France 
don’t. ConClusions: Our results underline the country difference of arbitration 
between public policies such as public health, and industrial or innovation policy. 
Among tested variables, it appears that the regulation of drug pricing and market 
access, or the macroeconomic impact of pharmaceutical industry in a country con-
tribute to determine the scope of HTA policies.
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CliniCal, EPidEmiologiCal and EConomiC mEtriCs diffErEnCE BEtwEEn 
HPV-rElatEd and traditional HEad and nECk CanCErs
Coughlan D.
NUI Galway, Galway, Ireland
Excessive smoking and alcohol consumption were the traditional causal factors in 
many head and neck cancers in the United States and Western Europe. However, 
the Human papilloma Virsus (HPV) is now responsible for up to 80% of cancers of 
the oropharynx. HPV-related oropharyngeal cancers are a distinct clinical, epide-
miological and molecular entity. This poster will show that the metrics used to 
describe the burden of a cancer to policy makers are very nuanced. As the patients 
with HPV-associated oropharyngeal cancers are younger and healthier individuals, 
they have been shown to have a better prognosis than traditional head and neck 
cancers. The goal of treatment has shifted from mortality to morbidity in these can-
cers. Measures of morbidity (functional status) are now important considerations in 
treatment options. This poster will compare and contrast various epidemiological 
measures - Incidence /100,000, Prevalence, Years of Life Lost, Mortality to Incidence 
Ratio with respect to HPV-related and unrelated head and neck cancers. Finally, 
we will discuss the economic metrics (e.g. Disability adjusted life years, Years of 
working age lost) used to portray a cancer and make a link with research funding 
in various countries. The question posed is whether mortality or morbidity should 
predominate in resource/research allocation decisions?
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1University of York, York, UK, 2University of Sheffield, Sheffield, UK
objeCtives: How health care decision makers arrange their appraisal process of 
new health care technologies have direct impact on population health. However, 
no consensus exists on how the appraisal process should be designed to maxim-
ise population health or societal welfare. The purpose of this work is to develop 
a simple analytic framework that enables analysis of the different stakeholders’ 
(decision makers and manufacturers) payoffs from alternative appraisal pro-
cesses. Methods: The analytic framework outlined in the paper is based on 
viewing the appraisal processes as a diagnostic test aimed at identifying cost-
effective (true positives) and cost-ineffective (true negative) technologies. Based 
on this characterisation pay-off functions are formalised to analyse how design 
and operation of the appraisal process impacts population health and manufac-
turers’ earnings. Results: The framework identifies those factors that have the 
greatest influence on population health and manufactures payoffs and illustrates 
how this leads to conflicting interests towards how the appraisal process should 
be set up and operated. It is demonstrated that there is no uniquely optimal way 
to design and operate the appraisal of new health care technologies, since optimal 
design and operation depends on the price of technologies that undergo appraisal. 
The analysis also shows that operating a given reimbursement system implies a 
trade-off between incentivising cost-effective pricing (pricing below the threshold/
willingness to pay) and rejecting more cost-effective technologies (increasing the 
proportion of false negatives). It is further demonstrated how the framework can 
be used to gain insight into current policy questions including who should bear the 
burden of proof and how rigorous the process should be. ConClusions: There is 
no unique way to design and operate the appraisal of health care technologies in 
order to maximise population health or societal welfare. Improving health or soci-
etal welfare through the appraisal process requires careful consideration of payoffs 
and incentives of all stakeholders.
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(msu)
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objeCtives: The generation of evidence in the early development of a technology 
is a bottle neck for uncertainty in decision making. Health economic modeling can 
support the assessment of early innovation, but complex modeling approaches are 
criticized for being “black boxes” which in turn reduce their acceptance in health 
policy. Methods: MCDA can address the gap about what matters to health care 
decision makers and data collection by explicitly structuring decision criteria. The 
combination of MCDA modeling and health economic modeling implies a potential 
for gaining efficiency. The simulation model of the intervention for stroke, the MSU, 
is analyzed regarding application of MCDA. Results: Experts and stakeholders can 
support the: 1) Definition of model factors e.g. outcome parameter, which is gener-
ally accepted (Barthel-Index for Stroke outcome); 2) Evidence collection e.g. is the 
data valid? (outcome of thrombolysis); 3) Model structure e.g. interrelation between 
input parameters (stroke incidence, risk factors and population); 4) Validation of 
a model e.g. reassessment of step 1-3; and 5) Final analysis by using MCDA e.g. 
importance of economic vs. medical benefit. ConClusions: The methodological 
combination is advantageous because simulation modeling as well as MCDA have 
a similar sequence of events. The simulation output, which is commonly validated 
by technical and medical experts, can gain validity by the heterogeneous perspec-
tives of participating stakeholders in the validation process. For example, this raises 
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bACkgRound: Colorectal cancer (CRC) screening in Spain uses a fecal-occult 
blood test (FOBT) for screening and colonoscopy as diagnostic tool. Adenomas 
constitute the most frequent findings of this colonoscopy, and the removal of 
these premalignant lesions is considered the main contributor to the reduction 
of mortality and incidence of CRC. There is no clear agreement regarding the 
risk classification of adenomas as well as the optimal surveillance strategy for 
each degree of risk. Genomics may contribute to further delineate individual risk, 
and its characterization is crucial for improving the effectiveness of surveillance 
strategies by targeting individuals who would benefit the most. objeCtive: To 
optimize, within a CRC screening program, surveillance of premalignant lesions 
using individual risk-based strategies, based on genetic analysis, that take into 
account benefits, harms and costs. Methods: A discrete-event simulation model 
that reproduces the process of screening and takes into account the costs at every 
stage, from invitation to screening to surveillance of findings will be upgraded. 
The natural history of the disease will be included, with special emphasis on the 
events after adenoma detection at screening colonoscopy. Based on the results of a 
study aimed at identifying common genetic variants associated with an increased 
susceptibility to develop colorectal adenomas, the risk of developing cancer or 
recurrent adenomas according to the clinical characteristics of the patients will 
be included in the model. The interval between surveillance colonoscopies will 
be optimized with the objective of minimizing the number of colonoscopies while 
keeping the same level of effectiveness, defined as the impact on incidence of 
advanced adenomas and cancer over time. IMPLICATIONS: Simulation models 
can help in the design of personalized screening strategies. Personalizing CRC 
screening through surveillance strategies may improve allocation of resources 
under cost constraints, minimize harms and maximize benefits of population-
based programs, affecting millions of people.
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For nearly 25 years, the most effective tool for containing public spending on 
pharmaceutical drugs in Germany is the formation of fixed reference price groups 
(FRPG) - the annual savings have continuously risen from 0.31 billion Euros in 1990 
to 4.32 billion Euros in 2009. Hereunder, the so-called “jumbo groups” (patent-free 
and patented substances) that were introduced with the SHI Modernization Act 
of 2004 have been of high importance. With the recently published, first-time call 
for benefit assessments of substances in the established market (April 2013), the 
Federal Joint Committee (FJC) has yet launched another potent mean of reducing 
costs. Unlike the early benefit assessment of new active ingredients where several 
substances have undergone scrutiny since January 2011, it is unclear what the 
outlook is for the substances in the established market. Therefore, the objective of 
the presentation is to assess whether a FRPG or a benefit assessment is to be pre-
ferred by pharmaceutical companies for established substances. Fixed reference 
price scenarios are calculated for therapeutically comparable substance classes 
within the call for benefit assessment of substances in the established German 
drug market. For the established substances, a risk assessment and benchmark 
is performed based on the criteria in the code of procedure of the FJC and the 
assessment of new active ingredients, respectively. The results of the ongoing FRPG 
scenario evaluation will be displayed as bar charts by savings in € . The risk assess-
ment is displayed in a tabular format. Apart from discussing the results of the 
FRPG calculations compared to the benefit assessment of established substances, 
the presentation discusses implications for international reference pricing, since 
the German market has been regarded as the last bastion of free pharmaceutical 
pricing for a long time.
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objeCtives: Socioeconomic factors are important components of Health 
Technology Assessment’s (HTA) institutionalization. If most of the countries 
have established HTA agencies, they required scientific expertise to emerge and 
become institutionalized. In a previous scientometric work, we did an analysis 
of scientific conditions of HTA emergence in the scientific literature. Our obser-
vation allowed us to link HTA research capacity and HTA institutionalization in 
a given country. Methods: In order to explore endogenous as well exogenous 
factors sustaining HTA expertise, we undertake a principal component analysis 
as multivariate analysis technique in order to establish which variable are more 
appropriate for the assessment of scientific expertise in the context of HTA public 
policy. Results: HTA national public policy could be ranked according to their 
academic expertise. Country HTA publications productivity matched in comparison 
with health expenses & gross product in several countries. Nevertheless this rank-
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reflects a preference on behalf of the decision maker. Reality does not always match 
the ideal of a fixed threshold.
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objeCtives: South America (SA) is a continent with 400 million people and occu-
pies 12% of the world’s territory. It is composed by 12 countries and 6.75% of its 
population is below the poverty line, as defined by UN. The proper distribution of 
financial health resources, through an HTA process in public systems is potentially 
essential to improve the quality of health care expenditure. The objective of this 
study is to understand the incorporation process of new health technologies and 
compare the general health status in each country, regarding the Objectives of 
the Millennium (OM). Methods: A public data collection was performed in offi-
cial sources linked to UN, to governments of SA and the Unión de las Naciones 
Suramericana (UNASUR). Results: The public health financing in SA countries 
was between 2.43% and 6.20% of the GDP. An HTA process in an institutionalized 
and specialized form is in place in only 3 countries (Argentina, Brazil and Peru). 
Bolivia, Chile, Colombia, Paraguay and Venezuela do not have a specialized HTA 
process and the other four countries have no HTA process at all. Regarding the OM 
the decrease in child mortality, increase in vaccination, increase in malaria and 
tuberculosis treatments are among the closest to be achieved in all countries. There 
is a linear positive correlation of OM with the Human Development Index and with 
the percentage of GDP invested in public health but not with having a HTA process 
in place. ConClusion: At this moment, there is no evidence that an HTA process 
in place helps SA countries to achieve the OM.
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objeCtive: The Balduzzi law (189/2012) introduced several changes aimed at pro-
moting the country’s development through a higher level of health protection and 
at bridging the gap left by the rationing of health care resource from the Spending 
Review (135/2012). Reducing the time to drug market access is one of the main pur-
poses. The aim of the research is a critical analysis of this law to understand its actual 
and future impact on the health care scenario. Methods: An evaluation of the laws 
issued in the last three years that aimed at regulating the drug market was carried out. 
To build a future scenario analysis, we focused our attention on the Balduzzi law and 
two of its articles (11 and 12) and on the new drugs approved by AIFA and commercial-
ized under the new regulation. Results: The changes that will have a major impact 
on the drug market are: the allocation of the medicines approved under centralized 
procedure in the non-negotiated C Class within 60 days from the publication in the 
Official Gazzette of the European Union and the direct placement of generics and bio-
similars in the reimbursement class of the originator without any price negotiation. As 
of now, a total number of 49 drugs have been included in the non-negotiated C Class, 
within this new group there are 15 first drug authorizations. ConClusion: The new 
reform can be potentially an interesting innovation to speed up market access, though 
the impact of including new drugs in the C class (at patient charge) before the price 
negotiation is still under debate. The increased competitiveness coming from having 
a faster introduction in the market of generics/biosimilars could lead to important 
savings for the National Healthcare System over the next years.
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A large number of factors point to an unavoidable rise in health care expenditure to 
13%-18% of Europe’s GDP by 2030, even with policy interventions or budget caps that 
aim to counterbalance these pressures. This growth in health care costs need not be 
undesirable especially so when higher spending on health care leads to improved health 
care quality and life expectancy. Therefore, the challenge is not “how do we reverse the 
growth of health care costs?” but “how can we best deploy the increasing resources spent 
on health care to create optimal benefits for the European population?” Health R&D is 
the key to being able to respond to this dilemma. Increased investment in R&D leads to 
improved health outcomes, long term efficiency gains, better productivity and high eco-
nomic yields. However, the outlook for Europe is not as positive as it could be. Recently, 
there has been a stagnation or even decline in European private and public investment 
in R&D, which is in sharp contrast with the much higher investments in the US. Private 
biopharmaceutical investments in health R&D, which are double the size of public health 
R&D, in 2011 actually decreased in absolute terms. Public R&D investments declined or 
stagnated in most European countries and will be further under pressure in the near 
future due to public budget deficits. Janssen commissioned the Deloitte European Center 
on Health Economics and Outcomes Research to set out the arguments in support of 
increased investment in health R&D in Europe. The paper demonstrates that, even in 
times of austerity, policymakers need to prioritise approaches that will enhance public 
R&D investments and adopt strategies that produce incentives for private enterprises 
so that the current decline in private sector investment is halted.
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How do onCology drug PriCEs Vary aCross Eu5, tHE unitEd statEs, 
and BriC markEts?
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questions about priority and importance of certain outcome parameters like the 
thrombolysis rates vs. the independence of patients after 3 months. Finally, the com-
bination of MCDA and simulation modeling contributes to a transparent analytic 
process and results in a more complex understanding of the technology.
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Although the EU Council stated that “All health systems in the EU aim to make provision, 
which is patient-centered and responsive to individual need”, unacceptable differences in 
access to orphan medicinal products (OMP) in the Member States of the European 
Union are identified. In the context of the 2010 Belgian EU presidency initiative 
on ‘Innovation and Solidarity’ and within the framework of the process on corpo-
rate responsibility in the field of pharmaceuticals, EU Commissioner Tajani there-
fore launched the project Mechanism of Coordinated Access to OMP.objeCtives: 
Designing a operational mechanism of coordinated access to OMP for patients, stake-
holders and Member States to provide, irrespective of the local conditions, access for 
patients with unmet medical needs and for whom these solutions would otherwise 
be out of reach – in an affordable and sustainable way (“real life access”). Methods: 
The project is managed by Belgium (NIHDI), supported by the European Commission 
and Eminet. Thirteen Member States participated, with the stakeholders (AIM, EPF, 
ESIP, Eurordis, CPME, EFPIA, EGA, EuropaBio, GIRP). Three Workpackages cover the 
different aspects of granting effective access to medicines: Identifying and assess-
ing a relevant orphan drug (assessment/evaluation) - Selection of target population 
and mechanisms of funding (structural access) - Treatment (individual access). 
Feasibility at present and opportunities for near future development of desirable 
activities were studied, and no-go solutions were documented and rejected in order 
to develop implementable scenarios for pilot projects and policy recommendations. 
Discussion: Although coordinated access at an European level will be organized on a 
voluntary basis, some sort of commitment from the participating partners is required. 
Moreover, it is crucial that the subsidiarity principle is not jeopardized or compro-
mised. Duplication of efforts will be avoided and previously made investments – in 
terms of financial and human resources, expertise and experience - (ex. by EUnet 
HTA, EMA COMP, EUCERD, CAVOD,…) will be valorized.
PHP219
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objeCtives: To look at the affordability of orphan medications across Europe and 
whether payer attitudes to high-price medications are changing in the face of ris-
ing health care expenditure and tighter budgets. Methods: A detailed review of 
7 EU markets (France, Germany, Italy, The Netherlands, Poland, Spain, UK) looking 
at payer attitudes and funding decisions for key orphan drugs and the political, 
economic and societal impact of these. A key focus of the research was insight into 
payer attitudes towards the evidence base for the purpose of pricing negotiations 
and how anecdotal evidence, such as Patient Reported Outcomes (PROs) and patient 
case studies, have an impact on decision-making. Detailed research was also under-
taken to ascertain the pricing levels achieved for a number of orphan drugs across 
Europe looking at payer thresholds and the implications of these for the purpose 
of reimbursement. Results: The research demonstrates that there is considerable 
variation in pricing levels across the European markets and difference in payer 
attitudes towards the way orphan drugs are funded. Overcoming evidence chal-
lenges in orphan diseases remains a headache for payers and scepticism remains 
around dosing, innovation and whether approaches such as “coverage with evidence 
development” are adequate and/or sustainable in the long-term following initial 
approval. ConClusions: The environment for orphan medicines in Europe is 
changing; and as the financial performance of European countries begins to diverge, 
so do attitudes towards the funding of orphan medicines. Orphan medicine prices 
are rarely justified on the basis of traditional cost-effectiveness thresholds and most 
markets still differentiate them from other pharmaceuticals. However, payers are 
afraid of uncertainty and, given the increasing number of orphan drugs and the 
often tentative evidence base at launch, may be forced by overwhelming financial 
necessity to make tougher decisions on funding.
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Decision making rules in health technology assessments are often based on a fixed 
willingness to pay threshold for the incremental cost effectiveness. This may be 
thought of as consistent with expected utility – with utility here defined in terms of 
Incremental Net Benefit (INB) – a combination of QALY gain and the threshold value. 
Alternative methods such as multi criteria decision analysis allow incorporation 
of other dimensions into the decision space. These seek to explore whether utility 
may be driven by factors other than simple QALY gain. Prospect theory suggests 
that decision makers are concerned in practice with the ‘size’ of a given decision. 
Also, they handle investment and disinvestment differently. In the Irish State, every 
new drug is examined. In order to look at actual decisions, lifetime QALY gains were 
extracted from completed economic evaluations submitted to the Irish health care 
payer. Total spend on these was calculated using a combination of the payer reim-
bursement database and predicted budget impact. Real choices indicate that where 
the budget impact is relatively small the drug is more likely to be reimbursed even 
with a comparatively small QALY gain. Technologies in areas of cancer and orphan 
diseases often lie outside of the threshold where a technology would be accepted. 
Decision makers are faced with choices with varying degrees of risk. Choices asso-
ciated with a low budget impact are deemed to be less risky. This is pragmatic; it 
